# Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients

> **NCT01245582** · PHASE3 · WITHDRAWN · sponsor: **Sanofi**

## Conditions studied

- Hepatic Neoplasm Malignant

## Interventions

- **DRUG:** oxaliplatin (SR96669)
- **DRUG:** capecitabine
- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT01245582
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-07
- **Primary completion:** 2014-02
- **Final completion:** 2015-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2011-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245582, "Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01245582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*